XTAE
KDST
Market cap31mUSD
Apr 29, Last price
2,693.00ILS
1D
4.70%
1Q
90.05%
Jan 2017
-94.90%
IPO
-92.73%
Name
Kadimastem Ltd
Chart & Performance
Profile
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | |||||||||
Cost of revenue | 12,913 | 17,189 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (12,913) | (17,189) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 200 | (167) | |||||||
Tax Rate | |||||||||
NOPAT | (13,113) | (17,022) | |||||||
Net income | (12,048) -46.97% | (22,718) -13.54% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 5,732 | 5,475 | |||||||
BB yield | -2.28% | -1.37% | |||||||
Debt | |||||||||
Debt current | 5,490 | 5,570 | |||||||
Long-term debt | 2,144 | 4,524 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 3,653 | 68 | |||||||
Net debt | 3,479 | 3,702 | |||||||
Cash flow | |||||||||
Cash from operating activities | (11,087) | (19,996) | |||||||
CAPEX | (23) | (640) | |||||||
Cash from investing activities | 333 | (656) | |||||||
Cash from financing activities | 8,590 | 3,724 | |||||||
FCF | (10,572) | (18,711) | |||||||
Balance | |||||||||
Cash | 4,155 | 6,392 | |||||||
Long term investments | |||||||||
Excess cash | 4,155 | 6,392 | |||||||
Stockholders' equity | (243,453) | (204,537) | |||||||
Invested Capital | 249,070 | 212,062 | |||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 42,424 | 34,872 | |||||||
Price | 5.93 -48.39% | 11.49 -66.45% | |||||||
Market cap | 251,574 -37.21% | 400,679 -50.61% | |||||||
EV | 255,053 | 404,381 | |||||||
EBITDA | (10,625) | (15,249) | |||||||
EV/EBITDA | |||||||||
Interest | 252 | ||||||||
Interest/NOPBT |